Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 6/2010

01.12.2010 | Original Article

Complement-mediated bacteriolysis after binding of specific antibodies to drug-resistant Pseudomonas aeruginosa: morphological changes observed by using a field emission scanning electron microscope

verfasst von: Jun Tanaka, Takashi Nakae, Takatoshi Onoe, Yoshitaka Horiuchi, Hiroyoshi Miyamoto, Jun Adan-Kubo, Hiroaki Adachi, Yasuo Ono

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

A bactericidal mechanism mediated by human serum was investigated by a field emission scanning electron microscope and a strain of drug-resistant Pseudomonas aeruginosa. When the bacteria were treated with meropenem, a carbapenem antibiotic, spheroplasts and bulges (spheroidization) appeared after 1–3 h. When 40% serum was added to the bacteria, the bacteria agglutinated within 2 min and then lysed after 5–30 min. Immunoelectron micrographic analyses showed dispositions of complement component C9 molecules on the cell surface of lysed bacteria by the serum treatment that might suggest formation of a membrane attack complex. Immunoglobulin G (IgG) depletion from the serum diminished the lytic activity and adding human intravenous immunoglobulin (IVIG) restored it, suggesting that lysis was induced by specific IgG binding to the bacteria. IVIG may help patients with less IgG against bacteria to overcome severe infection.
Literatur
1.
Zurück zum Zitat National Nosocomial Infection Surveillance System. National nosocomial infection surveillance (NNIS) system report: data summary from January 1992 through June 2004. Am J Infect Control. 2004;32:470–85.CrossRef National Nosocomial Infection Surveillance System. National nosocomial infection surveillance (NNIS) system report: data summary from January 1992 through June 2004. Am J Infect Control. 2004;32:470–85.CrossRef
2.
Zurück zum Zitat Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother. 2005;49:3663–7.PubMedCrossRef Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother. 2005;49:3663–7.PubMedCrossRef
3.
Zurück zum Zitat Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50:43–8.PubMedCrossRef Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50:43–8.PubMedCrossRef
4.
Zurück zum Zitat Mikolajczyk MG, Concepcion NF, Wang T, Fraizer D, Golding B, Frasch CE, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11:1158–64.PubMed Mikolajczyk MG, Concepcion NF, Wang T, Fraizer D, Golding B, Frasch CE, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol. 2004;11:1158–64.PubMed
5.
Zurück zum Zitat Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983;147:1090–8.PubMed Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983;147:1090–8.PubMed
6.
Zurück zum Zitat Nakae T, Hirayama F, Hashimoto M. Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1. Kansenshogaku Zasshi. 2002;76:195–202.PubMed Nakae T, Hirayama F, Hashimoto M. Neutralizing activity of human immunoglobulin preparation against toxic shock syndrome toxin-1. Kansenshogaku Zasshi. 2002;76:195–202.PubMed
7.
Zurück zum Zitat Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631–8.PubMedCrossRef Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631–8.PubMedCrossRef
8.
Zurück zum Zitat Yanagisawa C, Hanaki H, Natae T, Sunakawa K. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother. 2007;13:368–72.PubMedCrossRef Yanagisawa C, Hanaki H, Natae T, Sunakawa K. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother. 2007;13:368–72.PubMedCrossRef
9.
Zurück zum Zitat Masaoka T, Hasegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother. 2000;48:199–217. Masaoka T, Hasegawa H, Takaku F, Mizoguchi H, Asano S, Ikeda Y, et al. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother. 2000;48:199–217.
10.
Zurück zum Zitat Ono Y, Ito T, Watanabe T, Koshio O, Tansho S, Ikeda T, et al. Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria. J Infect Chemother. 2004;10:234–8.PubMed Ono Y, Ito T, Watanabe T, Koshio O, Tansho S, Ikeda T, et al. Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria. J Infect Chemother. 2004;10:234–8.PubMed
11.
Zurück zum Zitat Nakae T, Tanaka J, Nakano A, Ono Y. Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant Pseudomonas aeruginosa. Jpn J Antibiot. 2008;61:379–87.PubMedCrossRef Nakae T, Tanaka J, Nakano A, Ono Y. Complement-mediated bactericidal effect of antibodies in human intravenous preparation against multi-drug resistant Pseudomonas aeruginosa. Jpn J Antibiot. 2008;61:379–87.PubMedCrossRef
12.
Zurück zum Zitat Fujita M, Matsushita M, Endo Y. The lectin-complement pathway: its role in innate immunity and evolution. Immunol Rev. 2004;198:185–202.PubMedCrossRef Fujita M, Matsushita M, Endo Y. The lectin-complement pathway: its role in innate immunity and evolution. Immunol Rev. 2004;198:185–202.PubMedCrossRef
13.
Zurück zum Zitat Mastellos D, Morikis D, Isaacs SN, Holland MC, Strey CW, Lambris JD. Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res. 2003;27:367–86.PubMedCrossRef Mastellos D, Morikis D, Isaacs SN, Holland MC, Strey CW, Lambris JD. Complement: structure, functions, evolution, and viral molecular mimicry. Immunol Res. 2003;27:367–86.PubMedCrossRef
14.
Zurück zum Zitat Rosado CJ, Buckle AM, Law RH, Butcher RE, Kan WT, Bird CH, et al. A common fold mediates vertebrate defense and bacterial attack. Science. 2007;317:1548–51.PubMedCrossRef Rosado CJ, Buckle AM, Law RH, Butcher RE, Kan WT, Bird CH, et al. A common fold mediates vertebrate defense and bacterial attack. Science. 2007;317:1548–51.PubMedCrossRef
15.
Zurück zum Zitat Tschopp J, Masson D, Stanley KK. Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature (Lond). 1986;322:831–4.CrossRef Tschopp J, Masson D, Stanley KK. Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature (Lond). 1986;322:831–4.CrossRef
16.
Zurück zum Zitat DiScipio RG, Hugli TE. The architecture of complement component C9 and poly(C9). J Biol Chem. 1985;260:14802–9.PubMed DiScipio RG, Hugli TE. The architecture of complement component C9 and poly(C9). J Biol Chem. 1985;260:14802–9.PubMed
17.
Zurück zum Zitat DiScipio RG, Berlin C. The architectural transition of human complement component C9 to poly(C9). Mol Immunol. 1999;36:575–85.PubMedCrossRef DiScipio RG, Berlin C. The architectural transition of human complement component C9 to poly(C9). Mol Immunol. 1999;36:575–85.PubMedCrossRef
18.
Zurück zum Zitat Nusinow SR, Zuraw BL, Curd JG. The hereditary and acquired deficiencies of complement. Med Clin N Am. 1985;69:487–504.PubMed Nusinow SR, Zuraw BL, Curd JG. The hereditary and acquired deficiencies of complement. Med Clin N Am. 1985;69:487–504.PubMed
19.
Zurück zum Zitat Trautmann M, Heinemann M, Zick R, Möricke A, Seidelmann M, Berger D. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis. 1998;17:754–60.PubMedCrossRef Trautmann M, Heinemann M, Zick R, Möricke A, Seidelmann M, Berger D. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis. 1998;17:754–60.PubMedCrossRef
20.
Zurück zum Zitat Horii T, Kobayashi M, Sato K, Ichiyama S, Ohta M. An in vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J Antimicrob Chemother. 1998;41:435–42.PubMedCrossRef Horii T, Kobayashi M, Sato K, Ichiyama S, Ohta M. An in vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J Antimicrob Chemother. 1998;41:435–42.PubMedCrossRef
21.
Zurück zum Zitat Sumita Y, Tada S, Nouda H, Okuda T, Fukasawa M. Mode of action of Meropenem, a new carbapenem antibiotic. Chemotherapy 1992;40 Suppl 1:90–102. Sumita Y, Tada S, Nouda H, Okuda T, Fukasawa M. Mode of action of Meropenem, a new carbapenem antibiotic. Chemotherapy 1992;40 Suppl 1:90–102.
22.
Zurück zum Zitat Tschopp J, Engel A, Podack ER. Molecular weight of poly(C9): 12 to 18 C9 molecules form the transmembrane channel of complement. J Biol Chem. 1984;259:1922–8.PubMed Tschopp J, Engel A, Podack ER. Molecular weight of poly(C9): 12 to 18 C9 molecules form the transmembrane channel of complement. J Biol Chem. 1984;259:1922–8.PubMed
23.
Zurück zum Zitat Skansén-Saphir U, Andersson J, Björk L, Ekberg C, Fehniger TE, Henter JI, et al. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol. 1998;47:229–35.PubMedCrossRef Skansén-Saphir U, Andersson J, Björk L, Ekberg C, Fehniger TE, Henter JI, et al. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol. 1998;47:229–35.PubMedCrossRef
24.
Zurück zum Zitat Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57:112–8.PubMedCrossRef Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004;57:112–8.PubMedCrossRef
Metadaten
Titel
Complement-mediated bacteriolysis after binding of specific antibodies to drug-resistant Pseudomonas aeruginosa: morphological changes observed by using a field emission scanning electron microscope
verfasst von
Jun Tanaka
Takashi Nakae
Takatoshi Onoe
Yoshitaka Horiuchi
Hiroyoshi Miyamoto
Jun Adan-Kubo
Hiroaki Adachi
Yasuo Ono
Publikationsdatum
01.12.2010
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 6/2010
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-010-0074-4

Weitere Artikel der Ausgabe 6/2010

Journal of Infection and Chemotherapy 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.